CompletedNot Applicable

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)

France172 participantsStarted 2019-01-24

Plain-language summary

ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. 1\) Patient curatively treated within the past 3 years for:
. Patient with no evidence of any invasive tumor at inclusion (clinical and, if any, radiological exams).
. Age ≥ 18 years
. Availability of HPV genotyping of the treated cancer and/or archived tumor tissue available.
. Patient who a follow-up visit is scheduled in the including center at least twice a year.
. Patient being affiliated to the French social security.
. Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

. Patient presenting with active invasive tumor masses (e.g. stage IV cancer).
. Patient deprived from ability to decide on her own or placed under the authority of a tutor.
. Patient unable to have a regular follow up for geographical, social or psychological reasons.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Sensitivity of plasma circulating tumor DNA detection as a test to detect any (local or distant) relapse in patients who have been curatively treated for HPV-induced invasive pelvic cancer (cervix, anal canal, vagina, vulva, penis).

Timeframe: up to 36 months

Specificity of plasma circulating tumor DNA detection as a test to detect any (local or distant) relapse in patients who have been curatively treated for HPV-induced invasive pelvic cancer (cervix, anal canal, vagina, vulva, penis).

Timeframe: up to 36 months

Trial details

NCT IDNCT03739775

SponsorInstitut Curie

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-19

View on ClinicalTrials.gov More HPV Positive Pelvic Cancer trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. 1\) Patient curatively treated within the past 3 years for:
. Patient with no evidence of any invasive tumor at inclusion (clinical and, if any, radiological exams).
. Age ≥ 18 years
. Availability of HPV genotyping of the treated cancer and/or archived tumor tissue available.
. Patient who a follow-up visit is scheduled in the including center at least twice a year.
. Patient being affiliated to the French social security.
. Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

. Patient presenting with active invasive tumor masses (e.g. stage IV cancer).
. Patient deprived from ability to decide on her own or placed under the authority of a tutor.
. Patient unable to have a regular follow up for geographical, social or psychological reasons.

What they're measuring

Timeframe: up to 36 months